Evergreen Capital Management LLC purchased a new stake in InMode Ltd. (NASDAQ:INMD - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 180,887 shares of the healthcare company's stock, valued at approximately $3,209,000. Evergreen Capital Management LLC owned approximately 0.26% of InMode at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently bought and sold shares of INMD. CWM LLC lifted its stake in shares of InMode by 106.4% during the first quarter. CWM LLC now owns 2,369 shares of the healthcare company's stock valued at $42,000 after buying an additional 1,221 shares during the period. Orion Capital Management LLC purchased a new position in shares of InMode during the 4th quarter worth $65,000. Summit Securities Group LLC purchased a new position in shares of InMode during the 1st quarter worth $70,000. Lazard Asset Management LLC lifted its stake in shares of InMode by 6,128.7% during the 4th quarter. Lazard Asset Management LLC now owns 6,291 shares of the healthcare company's stock worth $105,000 after purchasing an additional 6,190 shares during the period. Finally, Bridgefront Capital LLC purchased a new position in shares of InMode during the 4th quarter worth $178,000. Hedge funds and other institutional investors own 68.04% of the company's stock.
Analysts Set New Price Targets
Several equities analysts recently weighed in on INMD shares. Canaccord Genuity Group reiterated a "hold" rating and set a $15.00 target price on shares of InMode in a research report on Friday, July 11th. Needham & Company LLC reiterated a "hold" rating on shares of InMode in a report on Wednesday, July 30th. Finally, Barclays cut their price objective on shares of InMode from $24.00 to $21.00 and set an "overweight" rating on the stock in a report on Wednesday, July 30th. One equities research analyst has rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $18.04.
Check Out Our Latest Stock Analysis on INMD
InMode Stock Up 0.7%
Shares of INMD stock traded up $0.10 during mid-day trading on Wednesday, reaching $14.51. The company's stock had a trading volume of 678,479 shares, compared to its average volume of 1,265,500. The company's 50 day simple moving average is $14.49 and its 200-day simple moving average is $15.48. InMode Ltd. has a 12-month low of $13.14 and a 12-month high of $19.85. The firm has a market capitalization of $917.18 million, a PE ratio of 5.87 and a beta of 2.00.
InMode (NASDAQ:INMD - Get Free Report) last issued its earnings results on Wednesday, July 30th. The healthcare company reported $0.47 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.03). InMode had a net margin of 44.50% and a return on equity of 18.38%. The business had revenue of $95.60 million during the quarter, compared to analysts' expectations of $98.45 million. During the same period in the prior year, the business posted $0.34 EPS. The business's revenue was up 10.6% on a year-over-year basis. As a group, research analysts anticipate that InMode Ltd. will post 1.75 EPS for the current fiscal year.
About InMode
(
Free Report)
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
Featured Stories
Before you consider InMode, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InMode wasn't on the list.
While InMode currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
